Deprescribing Seen in T2D Care - Summary - MDSpire
From the Journals

Deprescribing Seen in T2D Care

Researchers examine medication changes in practices with lifestyle medicine access

Share

In a retrospective analysis of electronic health records for 650 patients with type 2 diabetes, researchers found that access to lifestyle medicine in primary care often resulted in the deprescribing of glucose-lowering medications. An overall reduction in body mass index (2 kg/m²), glucose levels (25%), and hemoglobin A1c (13%) was observed among those who underwent deprescribing, with no serious adverse events reported. The study highlights how integrating lifestyle changes can be beneficial in managing type 2 diabetes treatment effectively.

Original Source(s)

Deprescribing Seen in T2D Care

  • by Kathryn Wighton

  • April 6, 2026

Related Content

Was the GLP-1 Problem Always Cost?

A JAMA Viewpoint argues the BALANCE model targets the leading cause of discontinuation.

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

PFAS Exposure Linked to Faster Epigenetic Aging 

Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64 

  • April 1, 2026

  • 2 min